31st Mar 2016 10:26
LONDON (Alliance News) - Bioscience contract research organisation Cyprotex PLC on Thursday said it has launched a new 3D liver model for detecting hepatotoxic potential.
Hepatotoxicity is a major cause of drug attrition, Cyprotex said, and has proven difficult to detect in pre-clinical animal studies.
Human cellular models, like the one launched by Cyprotex, have shown promise as an alternative to animal-based testing for hepatotoxicity, the company said.
"Developing 3D cell-based models has been a key focus of our research during the past 12 months. Not only are these models proving valuable for toxicology testing but they are also showing promise in efficacy and ADME testing, and are being used within a number of different industries," said Cyprotex Chief Executive Anthony Baxter.
Cyprotex shares were up 0.8% to 93.20 pence.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2016 Alliance News Limited. All Rights Reserved.
Related Shares:
CRX.L